Whatever Happened to the Biodefense Industrial Complex?
May 3 2005
Currently, the US biodefense market consists of a hodge-podge of small niche players blended with very few large biopharmas and select defense contractors. Despite some early encouraging signs the vision of a biodefense industrial complex is still far from being a reality. In the face of continued barriers to entry, should companies seek to invest in developing biodefense solutions? A closer look at the market suggests potential biodefense opportunities for both the defense industrial base and traditional pharmaceutical and biotech firms.
Download The Avascent Review No. 3
Author(s): Tim Garnett, Andrew Michaels